IV vs Local Stem Cell Therapy: Where the Cells Actually Go

If you've spent any time in Pattaya, you've seen the ads: a smiling clinic photo, a drip stand, and the promise of a "stem cell IV" to refresh, repair, or turn back the years. Then there's the other version — a single injection straight into a worn knee or shoulder. They get marketed as if they're interchangeable, two flavours of the same wonder treatment. They are not. The way stem cells are delivered changes where they end up in your body, how long they survive, and what — if anything — they do once they're there. This is a plain-language guide to that difference, written for people weighing up their options abroad. It's general education, not medical advice; what's right for you is a conversation with a doctor who knows your history.

What are the two main ways stem cells are given?

Most of the cells in question are mesenchymal stem cells (MSCs) — the type used in nearly all the "stem cell therapy" you'll see advertised. (If you want the basics of what these cells are, start with what are stem cells?) They're given two broad ways:

• Intravenously (IV / systemic) — infused into a vein, so they travel through the bloodstream.
• Locally (targeted) — injected directly into a specific tissue, such as the cartilage of a knee or an injured tendon.

This isn't a trivial detail. A systematic review of where MSCs actually travel after they're given — their biodistribution — found that the route of administration systematically changes the result: where the cells go depends heavily on how they were delivered ³. In other words, the route largely decides the destination.

Where do the cells actually go after an IV?

Here's the part the marketing rarely mentions. When MSCs are infused into a vein, the blood's first stop is the lungs — and the lungs act as a filter. MSCs are relatively large cells (around 20–30 micrometres across), bigger than the tiny capillaries of the lungs, so on that first pass through the circulation most of them get physically lodged there. Studies describe this "pulmonary first-pass effect" as a major obstacle to IV delivery, with the lungs trapping a large share of the infused cells before they can reach anywhere else ¹. Estimates vary, but roughly 50–80% of IV-infused cells lodge in the lungs initially ¹.

And they don't linger. Rather than quietly migrating off to repair a distant joint or organ, IV-infused MSCs are short-lived: in careful studies they're detectable mainly in the lungs for around 24 hours and then largely disappear, without engrafting and spreading throughout the body ². So the mental image of an IV "sending stem cells to wherever your body needs them" doesn't match what the cells are observed to do.

If the cells don't last, how could an IV help at all?

This is the honest crux of it. If most IV cells are trapped in the lungs and gone within a day, the benefit — when there is one — almost certainly doesn't come from the cells becoming new tissue. The leading explanation is paracrine signalling: while they're alive, MSCs release a mix of secreted factors and interact with the immune system, dampening overactive inflammation. Their best-described activity is this immune-modulating, signalling role rather than direct tissue replacement ⁴.

That reframing matters for expectations. An IV infusion is, at best, a brief systemic signal — not a delivery of permanent repair cells to every aching part of you. We unpack this "signal, not rebuild" idea more fully in what can stem cells actually do?

How does local injection compare?

A local injection works around the lung problem entirely. Because the cells are placed directly into the target tissue, they bypass the pulmonary filter and arrive where they're meant to be, with better retention at the site than the scattered, short-lived fate of an IV dose ³. That's the logic behind injecting into a specific joint rather than infusing into a vein and hoping the cells find their way: if the problem is one knee, putting the cells in that knee is a more direct route than the bloodstream.

This doesn't make local injection a guaranteed cure — the evidence even for well-studied targets remains limited, and the cells still appear to work mainly by signalling rather than wholesale rebuilding. But it does mean the delivery makes mechanistic sense: route matched to target.

Does the source of the cells change anything?

The cells themselves can come from a few places — bone marrow, adipose (fat) tissue, and umbilical cord are the common ones ⁵. A separate question from where they go is whose they are: autologous means your own cells, allogeneic means donor cells. That distinction affects sourcing, processing and regulatory status, and it's worth understanding alongside the route — we cover it in autologous vs allogeneic stem cells. Source and route are independent choices, and both are part of an honest conversation about any proposed treatment.

What we see at the clinic

The most common assumption we meet in Pattaya is that an IV "stem cell drip" is the strongest, most complete version of stem-cell therapy — a full-body upgrade in a bag. It isn't, and we say so plainly. The route is chosen for the clinical target: a systemic, immune-modulating context points one way, a single problem joint points another. Neither is a magic bullet, and we don't sell IV drips as a cure-all or as anti-ageing. Most stem-cell uses remain investigational, and we'd rather a visitor leave with accurate expectations than an oversold one. Broadly marketed IV "stem cell" infusions for general wellness are not an established, proven treatment, and reputable bodies have repeatedly cautioned against exactly that kind of marketing ⁶. If you're comparing providers, our guide to choosing a stem-cell clinic abroad lists the questions worth asking.

Common questions

Does an IV stem-cell drip send cells all over my body to heal it? That's the marketing picture, not what's observed. After an IV, most cells are caught in the lungs on the first pass and are short-lived, detectable mainly there for about a day rather than engrafting throughout the body ¹².

So is an IV useless? Not necessarily — but any benefit is thought to come from short-lived paracrine signalling and immune modulation while the cells are alive, not from them rebuilding tissue ⁴. That's a much narrower claim than "whole-body rejuvenation."

Why would a clinic inject into a joint instead of using an IV? A local injection bypasses the lung filter and places the cells directly in the target tissue, with better retention at the site — a more direct route when the problem is one specific area ³.

Which route is better? Neither is universally "better" — the route is chosen for the clinical target, and most uses remain investigational ³⁶. The right question isn't "IV or local?" in the abstract but "what's the evidence for this route, for my condition?"

Does it matter where the cells come from? Source (bone marrow, fat, or cord) and whether they're your own or a donor's are separate questions from delivery route, and both matter ⁵ — see autologous vs allogeneic stem cells.

Key takeaway

The route is not a detail — it's most of the story. An IV sends stem cells into the bloodstream, where the lungs trap roughly 50–80% on the first pass and the cells are short-lived ¹²; a local injection bypasses that filter and delivers them to the target tissue ³. In both cases, any benefit is thought to come from signalling, not from the cells becoming new tissue ⁴. Route is chosen for the clinical target, neither route is a magic bullet, most uses remain investigational, and a broadly marketed IV "stem cell drip" for general wellness is not an established, proven treatment ⁶ — so judge any offer by the evidence for your specific situation, with a doctor.